In our search for neworally active cephalosporins, we found that 7jS-[2-(2-amino-4-thiazolyl)-(Z)-2- and 9b, were prepared as reported in the ref3). The other pivaloyloxymethyl esters, 9c, 9d and 9e, were prepared via another procedure, which is shown in Scheme 2. Other esters llp~llw were prepared in the mannersimilar to that of 9e from the sodium salt of 5e and the corresponding halides. The latter halides were prepared from chloromethyl chlorosulfate (or chloromethyl iodide) and the corresponding carboxylic acids.
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The in vitro antibacterial activity of the compounds 6c~6e and the reference compounds was determined by the serial 2-fold agar dilution method and the results are given as MIC(jug/ml) in Table 1 . The activity of compounds 6c, 6d and 6e was as potent as that of parenteral cephalosporins (cefotaxime: CTXand cefmenoxime: CMX). The activity of these compoundsagainst Staphylococcus aureus was even superior to that of CTXand CMX. MICs were determined by the serial 2-fold agar dilution method. Test organisms and abbreviations: S.a., Staphylococcus aureus FDA209P; S.e., Staphylococcus epidermidis IAM 1296; Ex., Escherichia coli NIHJ JC-2; K.p., Klebsiella pneumoniae ATCC10031; P.m., Proteus mirabilis GN2425; P.v., Proteus vulgaris OX-19; P.a., Pseudomonas aeruginosa IFO 345 1 ; S.m., Serratia marcescens X-100.
While the oral cephalosporins CFIXand cefteram (CFTM) were highly active against Gram-negative bacteria, they showed only weak activities against Gram-positive bacteria. Cefuroxime (CXM), cefotiam (CTM) and cefaclor (CCL) showed less potent activity than 6c, 6d and 6e against both Grampositive and Gram-negative bacteria.
The pivaloyloxymethyl esters of these compounds (6a~6e) were prepared to estimate the oral absorption in rodents. The pivaloyloxymethyl esters are generally accepted as useful prodrug esters in oral administration of jS-lactam antibiotics3A).
The results are shown in Table 2 .
It is interesting to note that 9e, the methyl substituted analogue of 9d, exhibited higher oral absorption than 9d in both rats and mice. The oral absorption bioavailability of 9e was higher than those of CFTM-PI and cefuroxime axetil (CXM-AX) in both rats and mice.
As the pivaloyloxymethyl ester of 6e gave good urinary recovery and oral absorption, several kinds of esters other than pivaloyloxymethyl ester of 6e were orenared and evaluated. The results are shown in Table 3 . No better ester than pivaloyloxymethyl were found. The 1-methylpyrrolylcarbonyloxymethyl ester (lip) was moderately well absorbed orally.
A comparison test of oral absorption between 9e
and CFTM-PI was conducted. In Figs. 1 and 2 , the serum levels of 6e and CFTMafter oral administration of 9e and CFTM-PI in mice and rats are shown. The serum level of 6e was equal to that of CFTM in mice and about two times as high as that of CFTMin rats. Moreover, T1/2 of 6e in serum was about two times as long as that of CFTMin both mice and rats. In consideration of these pharmacokinetic data together with the antibacterial activities of 6e, compound9e was evaluated as a good oral cephalosporin. E x periment al IR spectra were recorded on a Hitachi model EPI-G3 spectrophotometer.
NMR spectra were recorded on Nihon Denshi a FX-270 (270 MHz) spectrometer using TMSas an internal standard. Urinary recovery of6 (iv)
b Mean+SD (n=3), male JCL-SD rats. c A group of eight male SLC-ICRmice was housed in each cage. d As suspension in a 0.5%-methyl cellulose solution.
NT:Not tested. a Relative bioavailability (%)= 100 x (AUC lip-llw, po)/(AUC 6e, iv).
7jg-[2-(2-Amino-4-thiazolyl)-(Z)-2-(methoxyimino)acetamido]-3-(3-methyl-1 ,2,4-thiadiazol-5-yl)thiomethyl~3-cephem-4-carboxylic
Acid (6e) To a suspension of25) (3.05g) and 4e (3.00g) in DMF(19 ml) was added triethylamine (2.64g). The mixture was stirred at room temperature for 2 hours. To the reaction mixture was added water (135 ml) and the insoluble material was filtered off with the aid of Celite. The filtrate was adjusted to pH 2.2 by the addition of2 n HC1.The precipitate was collected by filtration, washed with cold water and dried in vacuo to give a crude product (2.36g). The filtrate was further extracted by EtOAcseveral times. The combined extracts were washed with saturated aqueous NaCl and dried over MgSO4. Concentration of dried extracts gave also the crude product (2.69g); a total yield of crude product was 5.05g. The crude products were combined and purified b\ the preparative liquid chromatography on a reverse phase column, LiChroprep RP-8, with a mobile phase consisting of0.0 1 m phosphate buffer (pH 6.8), MeCN, and THF (80:10:10).
The fractions containing the product were concentrated in vacuo to a small volume and adjusted to pH2 by the addition of 2n HC1 at 0~5°C. The precipitate was collected, washed on a filter with cold water and dried in vacuo over phosphorus pentoxide. 
To an ice-cold solution ofDMF (1.67 g) in EtOAc (27ml) was added POC13 (2.17g) and the mixture was stirred at -5~0°C for 2 hours. To the resulting mixture was added 2-(2-formylamino-4-thiazolyl)-(Z)-2-(methoxyimino)acetic acid6) (3.27 g) and the mixture was stirred at -5~0°C for 2 hours. The reaction mixture was added to an ice-cold solution of a silyl derivative of 7-amino-3-(3-methyl-1,2,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid (4e), prepared by adding iV,O-bis(trimethylsilyl)acetamide (7.92 g) to a suspension of4e (4.34 g) in EtOAc (86ml), and the mixture was stirred at -5~0°C for 1.5 hours. To the reaction mixture was added a solution of water (26ml) and MeOH (5.5 ml) and the mixture was stirred for 30 minutes. The resulting crystals were collected by filtration, washed with EtOAcand dried in vacuo to give the product (3.49 g). Sodium Salt of 5e Compound 5e (590 mg) was dissolved in a solution of NaHCO3 (94mg) and H2O (17ml), and the solution was lyophilized to give the sodium salt of To an ice-cold solution of 5e (Na salt, 0.61 g) in DMF(3 ml) was added iodomethyl pivalate (0.41 g) and the mixture was stirred at 5°C for 1 hour. The mixture was poured into a mixture of EtOAc(30 ml) and water (10 ml) with stirring, and the organic layer was separated and washed with water (10 m x 2) and saturated brine (10 ml), then dried over MgSO4. 
To an ice-cold solution of8e (1.14g) in a mixture of MeOH(5ml) and THF (5ml) was added cone HC1 (1.5ml) and the mixture was stirred at 0~5°C for 8 hours. To the reaction mixture was added water (30ml) and the mixture was adjusted to pH2.5 by the addition of saturated aqueous NaHCO3.
The organic solvent was removed in vacuo and the resulting crystals were collected by filtration, washed with water and dried in vacuo to give 9e ( 
